Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Autobio Diagnostics CoSHSE:603658 -2.21%95 PB Ratio is 2.15 as of Aug. 27, 2026, which is 60% below its 10-year median of 5.36. GuruFocus rates SHSE:603658 with a GF Score™ of 95/100 and a GF Value™ of ¥40.43 (Modestly Undervalued). The stock has 3 warning signs investors should review. Among 783 Medical Devices & Instruments companies, Autobio Diagnostics Co ranks better than 52.23% on this metric.
The historical rank and industry rank for Autobio Diagnostics Co's PB Ratio or its related term are showing as below:
SHSE:603658'
s PB Ratio Range Over the Past 10 Years
Min: 1.79 Med: 5.36 Max: 24.65
Current: 2.15
During the past 13 years, Autobio Diagnostics Co's highest PB Ratio was 24.65. The lowest was 1.79. And the median was 5.36.
SHSE:603658's PB Ratio is ranked better than 52.23% of 783
companies
in the Medical Devices & Instruments industry
Industry Median: 2.15
vs SHSE:603658: 2.15
During the past 12 months, Autobio Diagnostics Co's average Book Value Per Share Growth Rate was 2.60% per year.
During the past 3 years, the average Book Value Per Share Growth Rate was 5.60% per year.
During the past 5 years, the average Book Value Per Share Growth Rate was 7.00% per year.
During the past 10 years, the average Book Value Per Share Growth Rate was 27.30% per year.
During the past 13 years, the highest 3-Year average Book Value Per Share Growth Rate of Autobio Diagnostics Co was 53.50% per year. The lowest was -26.20% per year. And the median was 12.70% per year.
The PB Ratio works the best for the businesses that earn most of their profit from their assets, e.g. banks and insurance companies.
Be Aware
Some businesses have very light assets, such as software companies or insurance agencies. The PB Ratio does not work well for these companies. Some companies even have negative equity, so the PB Ratio cannot be applied to them.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Medical Devices subindustry, Autobio Diagnostics Co's PB Ratio, along with its competitors' market caps and PB Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Autobio Diagnostics Co PB Ratio vs Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, Autobio Diagnostics Co's PB Ratio distribution charts can be found below:
* The bar in red indicates where Autobio Diagnostics Co's PB Ratio falls into.
The PB Ratio, or Price-to-Book ratio, or Price/Book, is a financial ratio used to compare a company's market price to its Book Value per Share. It is a ratio widely used to value stocks.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
It can also be calculated from the numbers for the whole company:
A closely related ratio is called Price-to-Tangible-Book. The difference between Price-to-Tangible-Book and PB Ratio is that book value other than intangibles are used in the calculation.
Autobio Diagnostics Co (SHSE:603658) has a PB Ratio of 2.15 as of Aug. 27, 2026. Price-to-Book ratio is the ratio of share price to a company's book value per share. View historical data on Autobio Diagnostics Co and its competitors. This is 60% below median its historical median of 5.36. Over the past decade, Autobio Diagnostics Co's PB Ratio has ranged from 1.79 to 24.65. According to the industry distribution chart, Autobio Diagnostics Co ranks #374 out of 783 companies in the Medical Devices & Instruments industry, placing it in the top 47.8%.
Is Autobio Diagnostics Co's PB Ratio too high?
Autobio Diagnostics Co's current PB Ratio of 2.15 is 60% below median its 10-year median of 5.36. Over the past 10 years, this metric has ranged from a low of 1.79 to a high of 24.65. The Medical Devices & Instruments industry median PB Ratio is 2.15. Autobio Diagnostics Co's value of 2.15 is 0% at this industry median. Based on the distribution chart, Autobio Diagnostics Co ranks #374 out of 783 companies in the Medical Devices & Instruments industry, which is above the industry midpoint. Overall, Autobio Diagnostics Co has a GF Score™ of 95/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Autobio Diagnostics Co's PB Ratio compare to ABT and SYK?
According to the Medical Devices & Instruments industry distribution chart, Autobio Diagnostics Co ranks #374 out of 783 companies for PB Ratio. This puts Autobio Diagnostics Co in the upper half of its industry. The industry median PB Ratio is 2.15. Autobio Diagnostics Co's value of 2.15 is 0% at this benchmark. Historically, Autobio Diagnostics Co's own PB Ratio has ranged from 1.79 to 24.65 over the past decade. While the company's 10-year median is 5.36 vs. the industry median of 2.15, Autobio Diagnostics Co has consistently been at the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good PB Ratio for a Medical Devices & Instruments company?
The median PB Ratio among Medical Devices & Instruments companies is 2.15, based on 783 companies in the industry. Companies in the top quartile (top 25%) have a PB Ratio significantly above this median, while those in the bottom quartile fall well below. However, PB Ratio should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Autobio Diagnostics Co's current PB Ratio of 2.15 is 0% at the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high PB Ratio mean?
A high PB Ratio can signal that a stock is expensive relative to its fundamentals. Price-to-Book ratio is the ratio of share price to a company's book value per share. View historical data on Autobio Diagnostics Co and its competitors. For the Medical Devices & Instruments industry, the median PB Ratio is 2.15 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Autobio Diagnostics Co's current PB Ratio is 2.15, which is 60% below median its own 10-year median of 5.36. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Autobio Diagnostics Co stock overvalued right now?
Based on GuruFocus' analysis, Autobio Diagnostics Co (SHSE:603658) is currently considered Modestly Undervalued. The stock's GF Value™ is ¥40.43, compared to a current price of ¥32.67 — trading 19.2% below its estimated fair value. The current PB Ratio is 2.15, which is 60% below median its 10-year median of 5.36 and 0% at the Medical Devices & Instruments industry median of 2.15. Autobio Diagnostics Co's overall GF Score™ is 95/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is PB Ratio calculated?
PB Ratio is calculated from a company's financial statements. For Autobio Diagnostics Co (SHSE:603658), the current PB Ratio is 2.15 as of Aug. 27, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Autobio Diagnostics Co (SHSE:603658) Overvalued in 2026?
Based on GuruFocus' analysis, Autobio Diagnostics Co stock appears to be undervalued.
The current stock price of ¥32.67 is trading 19.2% below its estimated GF Value™ of ¥40.43.
GuruFocus considers Autobio Diagnostics Co to be Modestly Undervalued.
Key valuation signals for SHSE:603658:
PB Ratio: 2.15 (60% below median its 10-year median of 5.36)
GF Value™: ¥40.43 vs. price of ¥32.67 (19.2% below fair value)
Industry Position: 0% at the Medical Devices & Instruments median (#374 of 783)
No single metric tells the full story. See the SHSE:603658 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Autobio Diagnostics Co Ltd is a clinical diagnostics company in China. It specializes in research and development, production, and sales of in vitro diagnostic reagents and instruments. The company's main products include immunoassay, microbiological, molecular diagnostic, and biochemical reagents, along with immunoassay, microbiological, molecular detection, and mass spectrometry instruments, as well as auxiliary testing devices.
95GF Score
Get the complete analysis for SHSE:603658
PB Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
SHSE:603658 has been successfully added to your 
